About Us

Part of the global pharmaceutical UBI Group, UBI Pharma consolidates the Group’s established values and builds a strong foundation of technology and production in the manufacture of pharmaceuticals, providing world-class pharmaceutical quality products. We develop innovative products such as non-monoclonal antibodies, novel small molecule drugs, and specialty injectables.

Company Overview

UBI Pharma Inc. is a CDMO (Contract Development and Manufacturing Organization) and CMO (Contract Manufacturing Organization) company that provides biopharmaceutical services and solutions for drug development and production with worldwide customers.

Our Vision

Empowering the world with affordable and high-quality medicines, making a positive impact on patients’ lives worldwide.

Our Mission

  • Delivering exceptional customer experiences by providing tailored, reliable, and cost-effective CDMO and CMO services that meet and exceed our clients’ expectations.
  • Collaborating with pharmaceutical partners to accelerate drug development and commercialization, fostering a healthier global community.
  • Investing in our people and technology to remain at the forefront of pharmaceutical innovation, enhancing our ability to address diverse healthcare needs.

UBI Pharma Inc., established on July 31, 2014. We are dedicated to comprehensive pharmaceutical solutions, proudly hold the distinction of being the first pharmaceutical company in Asia (except Japan) to pass the US FDA inspection for our injection filling production line.
With over 20 years experience in pharmaceutical industry, we focus on pioneering long-acting protein drugs and special injectables.
Having nearly 300 employees, with almost 30% possessing master’s degrees or above, our headquarters and manufacturing center are located in Hsinchu Industrial Park, encompassing an impressive 240,000 square feet. Additionally, we have set up clinical centers and business hubs in Taipei.


At UBI Pharma Inc., we possess several patented technologies, including the Long-Acting Protein Drug Development Technology, Long-Acting Small Molecule Technology Platform and Lyophilized Formulation Technology. Alongside our original Contract Manufacturing service (CMO), we also established the International Contract Development and Manufacturing (CDMO) one-stop service business model in 2018. Our exceptional team spans the spectrum of protein and specialty injectable drug development and mass production technology, as well as clinical, regulatory, and pharmaceutical manufacturing management, with the core mission to deliver top-notch services, accelerating our clients’ products from concept to the market.

Both our pharmaceutical personnel and quality management system are inherited from well-known international pharmaceutical company (GSK, GlaxoSmithKline), we have extensive experience in PIC/S GMP. Notably, we have produced Japanese encephalitis and tetanus vaccines for the Taiwan Centers for Disease Control (CDC), and we continue to serve as a trusted manufacturing partner for controlled drugs under the commission of TFDA of the Taiwan government. Furthermore, our international recognition is further affirmed by multinational official inspection such as US FDA, Japan PMDA, and Ukraine SMDC. As a testament to our global reach, our products have been exported to the United States, Japan, and other advanced countries, showcasing the exceptional manufacturing capacity, equipment scale, and personnel quality at UBI Pharma Inc.
Grounded in a robust foundation, we remain steadfast in our commitment to adhere to international PIC/S GMP guidelines for pharmaceuticals. Our current capacity for injectable vial is 11.2 million vials annually. And as part of our dedication to meeting the global demand, we expanded the production line from 2022, with an anticipated four-fold increase in production capacity upon startup.
Based in Taiwan, UBI Pharma Inc. holds firm to its belief in providing high-quality business, technology, and manufacturing services to global customers. With a focus on Europe, America, Japan, and beyond, we strive to disseminate our services and products worldwide, making significant contributions to the dynamic field of biotechnology and pharmaceuticals.